Rubin Lubomirov

1.1k total citations
38 papers, 717 citations indexed

About

Rubin Lubomirov is a scholar working on Oncology, Pharmacology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rubin Lubomirov has authored 38 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pharmacology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rubin Lubomirov's work include Pharmacogenetics and Drug Metabolism (10 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Rubin Lubomirov is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Rubin Lubomirov collaborates with scholars based in Spain, Switzerland and United States. Rubin Lubomirov's co-authors include Chantal Csajka, Amalio Telenti, Julia di Iulio, Matthias Cavassini, Laurent A. Décosterd, Margalida Rotger, Chin B. Eap, Aurélie Fayet, Mona Arab‐Alameddine and Hansjakob Furrer and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Rubin Lubomirov

37 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rubin Lubomirov Spain 13 374 239 162 132 128 38 717
Cheri E. Klein United States 16 293 0.8× 106 0.4× 106 0.7× 169 1.3× 139 1.1× 34 930
Daniel Röshammar Sweden 12 264 0.7× 149 0.6× 113 0.7× 78 0.6× 72 0.6× 22 564
William D. Fiske United States 11 309 0.8× 209 0.9× 99 0.6× 90 0.7× 83 0.6× 17 544
Ron van Schaik Netherlands 9 173 0.5× 97 0.4× 147 0.9× 113 0.9× 103 0.8× 29 553
Marelize Swart South Africa 14 244 0.7× 145 0.6× 232 1.4× 106 0.8× 96 0.8× 26 607
Neil Buss Switzerland 13 375 1.0× 252 1.1× 44 0.3× 61 0.5× 90 0.7× 17 655
Belle L. Lee United States 12 438 1.2× 204 0.9× 154 1.0× 102 0.8× 142 1.1× 15 835
Richard Granneman United States 11 331 0.9× 190 0.8× 113 0.7× 108 0.8× 277 2.2× 18 677
Marie‐Claude Gagnieu France 19 278 0.7× 71 0.3× 64 0.4× 145 1.1× 102 0.8× 63 889
A M Taburet France 19 239 0.6× 81 0.3× 95 0.6× 129 1.0× 236 1.8× 31 709

Countries citing papers authored by Rubin Lubomirov

Since Specialization
Citations

This map shows the geographic impact of Rubin Lubomirov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rubin Lubomirov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rubin Lubomirov more than expected).

Fields of papers citing papers by Rubin Lubomirov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rubin Lubomirov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rubin Lubomirov. The network helps show where Rubin Lubomirov may publish in the future.

Co-authorship network of co-authors of Rubin Lubomirov

This figure shows the co-authorship network connecting the top 25 collaborators of Rubin Lubomirov. A scholar is included among the top collaborators of Rubin Lubomirov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rubin Lubomirov. Rubin Lubomirov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lubomirov, Rubin, et al.. (2025). CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin. Clinical and Translational Science. 18(4). e70173–e70173.
2.
Moreno, Irene, Emiliano Calvo, Salvador Fudio, et al.. (2024). Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study. Marine Drugs. 22(4). 178–178. 3 indexed citations
3.
4.
Fudio, Salvador, et al.. (2023). A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study. Frontiers in Oncology. 13. 1152371–1152371. 4 indexed citations
5.
Fernández‐Teruel, Carlos, Salvador Fudio, & Rubin Lubomirov. (2021). Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 89(5). 585–594. 9 indexed citations
6.
Vieito, María, Santiago Ponce Aix, Luis Paz‐Ares, et al.. (2021). First-in-human study of PM14 in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 3078–3078. 1 indexed citations
7.
Fudio, Salvador, Josep Tabernero, Vivek Subbiah, et al.. (2020). Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis. Cancer Chemotherapy and Pharmacology. 87(1). 113–124. 3 indexed citations
8.
Rosing, Hilde, Rubin Lubomirov, Pablo Avilés, et al.. (2018). Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 158. 160–165. 5 indexed citations
9.
Fernández‐Teruel, Carlos, et al.. (2018). Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. Clinical Pharmacokinetics. 58(3). 363–374. 20 indexed citations
10.
Dobrinas, Maria, Mehdi Gholam‐Rezaee, Rubin Lubomirov, et al.. (2017). Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.. Experimental and Clinical Psychopharmacology. 25(5). 353–362. 12 indexed citations
11.
Lubomirov, Rubin, et al.. (2017). Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. The Pharmacogenomics Journal. 18(1). 180–186. 14 indexed citations
12.
Tong, Hoi Y., Cristina Lucía Dávila-Fajardo, Alberto M. Borobia, et al.. (2016). A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS ONE. 11(3). e0150456–e0150456. 16 indexed citations
13.
Dobrinas, Maria, Séverine Crettol, Beatrice Oneda, et al.. (2012). Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels. Pharmacogenetics and Genomics. 23(2). 84–93. 39 indexed citations
14.
Borobia, Alberto M., Rubin Lubomirov, Elena Ramı́rez, et al.. (2012). An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease. PLoS ONE. 7(7). e41360–e41360. 50 indexed citations
15.
Pellicer, Adelina, Joan Riera, María Carmen Bravo, et al.. (2012). Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. Pediatric Research. 73(1). 95–103. 38 indexed citations
16.
Lubomirov, Rubin, Julia di Iulio, Aurélie Fayet, et al.. (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics. 20(4). 217–230. 86 indexed citations
17.
Oliver, Paloma, Rubin Lubomirov, & Antonio J. Carcas. (2010). Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clinical Chemistry and Laboratory Medicine (CCLM). 48(5). 635–639. 7 indexed citations
18.
Iulio, Julia di, Aurélie Fayet, Mona Arab‐Alameddine, et al.. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics. 19(4). 300–309. 120 indexed citations
19.
Arab‐Alameddine, Mona, Julia di Iulio, Thierry Buclin, et al.. (2009). Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. Clinical Pharmacology & Therapeutics. 85(5). 485–494. 99 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cheri E. Klein Breakdown of academic impact, for papers by Daniel Röshammar Breakdown of academic impact, for papers by William D. Fiske Breakdown of academic impact, for papers by Ron van Schaik Breakdown of academic impact, for papers by Marelize Swart Breakdown of academic impact, for papers by Neil Buss Breakdown of academic impact, for papers by Belle L. Lee Breakdown of academic impact, for papers by Richard Granneman Breakdown of academic impact, for papers by Marie‐Claude Gagnieu Breakdown of academic impact, for papers by A M Taburet
Rankless by CCL
2026